Markets
Flock of sheep
Getty Images

73 Wall Street analysts cover Amazon, there are 72 on Meta, and 66 write about Nvidia — how many do we need?

Most of them have the same opinion, by the way (that you should buy those stocks).

In the 1990s, one of the most highly sought after jobs on Wall Street was stock research analyst.

Crunching some numbers, chatting to a few experts in the industry, and then writing (typically bullish) reports about stocks, in the hope that your insights would encourage investors or companies to do business with the financial institution you were employed by, was a great gig. The pay could be sky-high — some analysts made upward of $15 million a year in the glory days, per Bloomberg — and the CEOs of the companies in your remit wanted to talk to you. Crucially, analysts don’t personally have any skin in the game. Told everyone to buy a stock and it whiffed on earnings? You might lose face, and maybe some clients don’t take your calls, but you won’t lose any money. Onto the next one.

However, by the time I wandered wide-eyed into an investment bank’s research division in 2014 as an intern, the game had changed. By then, regulation quite rightly required a strict firewall between research and banking, blunting the conflict of interest between the two — and turning off the money hose for star analysts at big banks. Furthermore, as trading margins were squeezed, regulation tightened in Europe (MiFID II), AI emerged, and passive investing scooped up assets at breakneck speed, the headcount at research departments shrunk. As written in this great Bloomberg piece, published on January 8:

“Compared with their post-financial crisis peak, it’s estimated that the biggest banks globally have slashed the ranks of equity analysts by over 30% to lows not seen in at least a decade. Those who remain often cover twice, or even three times, as many companies.”

So, equity research has shrunk, and yet we still have 73 analysts — the highest number of any stock in the S&P 500, per FactSet data — all publishing price targets, building financial models in Excel, and writing reports about Amazon. How did that happen?

One explanation is that we have fewer analysts covering more companies in less depth. Another is that data aggregators like FactSet are collating more estimates and ratings from outside of the traditional 15 to 20 largest banks, including people working for boutique research houses, their own independent consulting companies, or smaller brokerages. Just 10 years ago, there were only 46 analysts covering Amazon.

But the simplest reason is that, due to Amazon’s sheer size and complexity, the $2.3 trillion behemoth is drawing the collective brainpower of both buy-side and sell-side analysts into its orbit. If you’re a fund manager, you need to understand Amazon and the rest of Big Tech because they make up more than one-third of the entire S&P 500 Index. And, if you’re an analyst who wants to make a name for themselves, it’s a lot easier to do so writing about stocks like Amazon, Meta, or Nvidia. While it’s an obvious correlation, it’s no less true: big stocks tend to get more attention.

Correlation between stock size and analyst coverage
Sherwood News

Now that we have stocks that are bigger than ever before, with eight companies over the $1 trillion market-cap threshold, it follows that analyst coverage remains incredibly concentrated on those names.

Indeed, Big Tech equities are the serious outliers, with their 50-plus analysts. The typical stock in the S&P 500 Index has just 23 analysts maintaining recommendations and forecasts on it, per FactSet data. Another outlier, Berkshire Hathaway, has just six analysts, because as a conglomerate, buying Berkshire Hathaway is really like buying a portfolio of other stocks and companies, plus a boatload of cash. (See: “So you invested in Berkshire Hathaway: What did you buy?”)

With 73 eyeballs on Amazon stock, and this many people analyzing the same amount of information, surely we should end up with a wonderful diversity of opinions? That, however, is not the case.

What’s most remarkable about the recommendations of these analysts is that they are almost all the same.

Of the 73 who cover Amazon, a whopping 69 — or some 95% — of them have positive recommendations on the stock, i.e. that you should buy (or be “overweight,” relative to a benchmark portfolio) the security. Out of the remaining analysts, three have a neutral view, and just one has an outright “sell” recommendation. The story isn’t that different for the rest of the BATMMAAN stocks either, Tesla aside.

Indeed, it turns out that a majority of the experts tend to subscribe to one overarching idea: that the eight Big Tech stocks, which drove so much of the market’s return last year, will (mostly) keep crushing it in 2025.

BATMMAAN stock coverage
Sherwood News

According to FactSet data, 95% of analysts covering Microsoft and Amazon, respectively, offer positive ratings for the two stocks — marking the companies with “overweight” or “buy” ratings — while 92% give the same judgement on Nvidia and 86% say the same for Broadcom. Meta has two analysts with “sell” ratings, Apple has four, and Tesla has a whopping 14, which is perhaps a reflection of the stock’s growing disconnect with the company’s fundamentals — a fact that some analysts think just doesn’t matter.

Why do we get this herding effect? I’ll summarize a few potential reasons that have been posited over the years, none of which are particularly satisfactory on their own.

  • The analysts are stupid. 

    • There’s certainly some truth to this some of the time (I have had many ideas about markets that have been very, very wrong), but it’s not a compelling argument in aggregate.

  • The analysts are smart.

    • Stocks usually go up. Ergo, if you were an alien who knew nothing else about markets and you got a job at fictional bank Citi Morgan Sachs as an analyst, your default recommendation would probably be: buy.

  • It’s in our nature to herd.

    • Study after study shows that we humans find it very hard to come up with original ideas when everyone has the same opinion or views things the same way. See: conformity experiments.

  • It’s in our nature to fear embarrassment.

    • Being loud and right is great work if you can get it — but being loud and wrong, when everyone else was saying the opposite, is a gamble many are not willing to take. Even if you have a different view, voicing it loudly can feel risky.

  • It’s not in the financial interests of the company that pays them.

    • This one stretches the practical limit of our regulations. By the letter of the law, banking and research departments shouldn’t know what the other one is working on anymore. However, research analysts know how their bread is buttered — if they have a huge red SELL sign hanging on a stock, it makes the jobs of their rainmaking banker colleagues trickier. Saying to the CEO of a company, “Hey, you should let us advise you on that huge merger you’re doing for fat fees,” is an uncomfortable pitch to make when someone else at your bank is saying that the company’s stock is about to tank.

  • The companies they cover will be mad at them.

    • Related to the one above, after you tell everyone you hate the stock, don’t expect the CEO to swan into your conference and shake your hand. In rare cases they will even threaten, or take, legal action. Some analysts build reputations on things as straightforward as corporate access (throwing great conferences, giving “market color” after an analyst breakfast, and simply being experts on the mechanics of the businesses they cover), which can be threatened by pissing off the companies they cover.

Throw all of those biases into a blender — and I’m sure many others that I’ve missed — and what do we get? We get 73 experts with an opinion on Amazon’s stock, 69 of which say: buy.

More Markets

See all Markets
markets

Intel sinks on news it will hang on to networking unit

Intel dropped in early trading Thursday after it disclosed plans to retain ownership of its networking unit following a strategic review of operations.

The unit, known as NEX, makes products like infrastructure processors, which do needed “housekeeping” tasks like running security checks, thereby freeing core Intel CPUs to do the higher-value operations. It also produces switches and controllers that manage and direct the flow of data to CPUs.

markets

Quantum computing stocks soar on return of bullish options bets

The calendar says December, but the price action is starting to look a lot more like September to me:

Quantum computing companies IonQ, Rigetti Computing, and D-Wave Quantum are all up at least 7% as of 11:04 a.m. ET, buoyed by a wave of bullish options activity.

  • Nearly 50,000 calls in IonQ have already changed hands, well above the 20-day average for a full session, with activity concentrated in strikes from $50 to $55 in contracts that expire between Friday and mid-January. Its put/call ratio is near 0.2, versus an average of over 1 for the past 20 sessions.

  • More than 65,000 calls have traded in Rigetti, a hair shy of its full 20-day average. Like IonQ, options activity has a bullish tilt, with a put/call ratio of about 0.7 versus a 20-day average of roughly 1.2.

  • D-Wave, which received positive commentary from Evercore ISI on Wednesday, isn’t seeing call activity as elevated as its peers, but the options action is also very skewed toward the bull side, with a put/call ratio of less than 0.3 versus a 20-session average of 0.7.

Pure-play quantum computing stocks nearly doubled from late August to late September amid heavy options market activity thanks to reports on government support for the sector, M&A activity, tech breakthroughs, and a flurry of price target hikes by Wall Street.

markets

Hims announces acquisition of Canadian telehealth firm Livewell

Hims & Hers rose in early trading after it announced its acquisition of Livewell, a Canadian telehealth company, marking its official entrance to that market.

The company announced in July that it would expand into Canada by 2026, taking advantage of the patent expiry for semaglutide, the active ingredient in Novo Nordisk’s blockbuster GLP-1s, Ozempic and Wegovy. Hims said Thursday that it would do that through an all-cash acquisition of Livewell.

Novo’s patent on semaglutide is set to expire in Canada in January. It would be the first time generics for the blockbuster GLP-1 drugs are available anywhere, and generic drugmaker Sandoz International has already announced plans to make copies of the drug. In the US, Hims sells copycat versions of Novo’s drugs, which has led to conflict between the companies.

On Wednesday, Hims announced that it would purchase YourBio, a device that uses “bladeless microneedles thinner than an eyelash” to collect blood samples, in another all-cash deal. According to its latest quarterly filing, the company had $345.8 million in cash and cash equivalents.

markets

Symbiotic tanks as company and SoftBank, its largest shareholder, announce offering of 10 million shares

Symbiotic was among the robotics companies that popped on Wednesday, gaining nearly 10% on the news that the Trump administration was on the precipice of a major push to support the industry.

So naturally, management thinks its a good time to sell shares — and its largest shareholder, SoftBank, agrees.

After the close on Wednesday, management announced an offering of 10 million shares, with 6.5 million of that as a primary offering from the company to raise money for general corporate purposes, and 3.5 million from a secondary sale by SoftBank, which owns over one-third of its shares.

The stock cratered on the announcement, giving back all of its one-day gains and then some.

Symbiotic went public in 2022 through a SPAC merger with a SoftBank-backed affiliate.

In October, SoftBank sold its entire $5.8 billion stake in Nvidia to meet an upcoming payment to OpenAI to finance its equity position in the company. Since SoftBank is slated to pay the ChatGPT maker more than $20 billion this month, it would appear that this is another step toward raising the needed cash for that position.

We’ll see if this divestment makes SoftBank founder Masayoshi Son cry.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.